MPO and inflammatory bowel disease: Specifically, we evaluated the effects of the XLTG11+5-ASA combination on IBD by measuring changes in the intestinal microbiota, conducting histopathological analyses, assessing intestinal barrier function, and measuring cytokine levels and myeloperoxidase (MPO) activity.